Clinical Trials
47 trialsNCT03179904 2026-05-05
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
NCT01723774 2025-12-09
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Washington University School of Medicine
Phase 2 Active not recruiting
NCT04272801 2025-10-22
POWER
University of Virginia
Phase 2 Active not recruiting
NCT03822468 2025-10-16
AMALEE
Novartis
Phase 2 Completed
NCT05549505 2025-08-29
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Arvinas Inc.
Phase 2 Completed
NCT03909152 2025-07-28
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03219476 2025-04-29
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT04294225 2025-01-28
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
Mayo Clinic
Phase 2 Completed
NCT04256941 2024-12-27
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT02648477 2024-03-19
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT03321981 2024-03-07
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Merus B.V.
Phase 2 Completed
NCT00921115 2023-05-19
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
University of Kansas Medical Center
Phase 2 Completed
NCT04436744 2023-02-02
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
Hoffmann-La Roche
Phase 2 Completed
NCT04075604 2022-08-10
CheckMate 7A8
Bristol-Myers Squibb
Phase 2 Completed
NCT03874325 2022-05-31
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT02000596 2022-05-27
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
University of Maryland, Baltimore
Phase 2 Terminated
NCT01234532 2022-05-03
0927GCC
University of Maryland, Baltimore
Phase 2 Terminated
NCT02269670 2022-04-05
Phase II Study of Everolimus Beyond Progression
Emory University
Phase 2 Terminated
NCT00405938 2021-11-18
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00256217 2021-05-11
Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
University of California, Irvine
Phase 2 Completed
NCT00871858 2021-02-24
HORGEN
Institut Bergonié
Phase 2 Completed
NCT00570323 2020-07-28
PACT001
Baylor Breast Care Center
Phase 2 Completed
NCT02441946 2020-06-17
neoMONARCH
Eli Lilly and Company
Phase 2 Completed
NCT02291913 2020-02-17
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00240071 2019-10-30
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.
University of Alabama at Birmingham
Phase 2 Completed
NCT00186121 2019-10-07
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
Stanford University
Phase 2 Completed
NCT00274469 2019-09-06
FIRST
AstraZeneca
Phase 2 Completed
NCT00179517 2019-07-17
Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT01394211 2018-07-26
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
University of Arizona
Phase 2 Terminated
NCT00728949 2018-06-06
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01776008 2018-05-08
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00932152 2017-10-19
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer
University of Pittsburgh
Phase 2 Terminated
NCT00661531 2017-04-12
Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy
Georgetown University
Phase 2 Terminated
NCT00481845 2017-02-07
Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
Stanford University
Phase 2 Terminated
NCT00573755 2016-02-05
Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Terminated
NCT01368263 2015-04-03
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT01151215 2014-07-25
MINT
AstraZeneca
Phase 2 Terminated
NCT00555477 2014-06-19
Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00057941 2014-05-12
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00354640 2013-06-24
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00005908 2013-03-19
Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00259090 2012-08-16
Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
AstraZeneca
Phase 2 Completed
NCT00357110 2010-12-21
@FAME
AstraZeneca
Phase 2 Completed